aTAG 2139

Key Product Details

Product Description

aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC₅₀ = 0.27 nM; D_max = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications.

Negative control aTAG 2139-NEG (Cat. No. 7575) also available.

Mouse DMPK properties are provided in the supplementary file (see below).

MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.

Licensing Information

Sold under exclusive license from C4 Therapeutics

Supplementary Information

Mouse DMPK properties are provided in the accompanying supplementary file.

Product Specifications for aTAG 2139

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for aTAG 2139

The following data is based on the product molecular weight 782.81.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	2.55 mL	12.77 mL	25.55 mL
2.5 mM	0.51 mL	2.55 mL	5.11 mL
5 mM	0.26 mL	1.28 mL	2.55 mL
25 mM	0.05 mL	0.26 mL	0.51 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Veits Development of an AchillesTAG degradation system and its application to control CAR-T activity. Curr.Res.Chem.Biol.

Product Documents for aTAG 2139